Alxerion´s Drug Discovery Technologies

We are proud to introduce Alxerion Biotech’s drug discovery technologies: High-Throughput Screening-EXOPLATFORM™ (HTS-EXOPLATFORM™), a powerful research tool to screen our Exosome Library, continuously providing new candidates for the pharmaceutical development of our pipeline; and our comprehensive Project Darwin-Lamarck.

HTS-EXOPLATFORM™

A Powerful Research Tool for Drug Discovery

Combining High-Throughput Screening (HTS) with our exosome technologies, we have developed the first generation of HTS-Exoplatfoms™ to screen our Libraries obtained from Project Darwin-Lamarck and to identify active compounds exhibiting therapeutic effects for cancer, Alzheimer’s Disease, cardiovascular disorders and antibiotics. Our technology provides extreme cost-effectiveness, highly efficient yields and allows the identification of the exosome´s effects in terms of its multi-target and real physiologically-induced actions.

Project Darwin-Lamarck

Deciphering the Unknown Biodiversity of the Southern Hemisphere to Discover Marvelous New Medicines

Project Darwin-Lamarck is an internationally collaborative project to explore and decipher the unknown biodiversity of Argentina for the development of innovative medicines of the XXI century. During the next four years, fourteen expeditions from Amazonia to Antarctica will permit the building of a Biobank of natural compounds containing innovative natural product libraries. Project Darwin-Lamarck has been designed strictly following the Nagoya Protocol on Access and Benefit-sharing, and our company has signed appropriate agreements with local governments and universities of Argentina. The main goal is to create the first Exosome Library composed of 30,000 species and more than 350,000 samples from plants, fungi, algae, microorganisms and insects. We are ready to decipher the cross-kingdom communication process mediated by ultra-purified exosomes and to identify the multi-target and real effects mediated by non-human exosomes on human cells and evaluate the existence of new small RNAs phenotypic effects and new CRISPR-like DNA interference genotypic effects.